USA |NYSE MKT |USD
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
| Shares Outstanding | 168.56M | Beta | 1.70 |
|---|---|---|---|
| Public Float | 127.38M | P/E Ratio | - |
| % Short of Float | - | Dividend (Yield) | - |
| Held by Insiders | 4.48% | Ex-Dividend Date | |
| Held by Institutions | 45.15% | IPO Date | Mar 6, 1992 |
| Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|
| Revenue | $773.00K | $3.52M | $4.99M |
| EBITDA | $-19.78M | $-15.99M | $-43.06M |
| Net Income | $-20.65M | $-11.71M | $-45.99M |
| Total Assets | $107.95M | $125.48M | $101.66M |
| Total Cash | $32.59M | $9.50M | $23.59M |
| Total Debt | $3.83M | $5.17M | $2.27M |
| Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|
| Revenue | $2.20M | $441.00K | $293.00K |
| EBITDA | $-8.64M | $-4.75M | $-14.04M |
| Net Income | $-7.82M | $-4.79M | $-1.42M |
| Total Assets | $131.21M | $134.75M | $127.93M |
| Total Cash | $60.81M | $62.00M | $56.21M |
| Total Debt | $2.72M | $2.90M | $3.55M |
| Year | Open | Close | Change |
|---|---|---|---|
| 2021 | $2.44 | $2.16 | -11.48% |
| 2021 | $1.75 | $2.44 | 39.43% |
| 2020 | $0.86 | $1.75 | 103.73% |
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Jun 10, 2022 | $1.44 | $1.48 | $1.38 | $1.40 | -6.67% | 559.47K |
| Jun 7, 2022 | $1.37 | $1.51 | $1.36 | $1.50 | 6.38% | 1.52M |
| Jun 21, 2022 | $1.36 | $1.41 | $1.34 | $1.41 | 2.92% | 1.03M |
Lineage cell therapeutics, inc is expected to report earnings on August 10 ,2022.
View More Details on Lineage cell therapeutics, inc's 'Earnings' Section
Lineage cell therapeutics, inc trades on the NYSE American stock market in USA under the ticker symbol "LCTX". Lineage cell therapeutics, inc’s stock symbol can also be displayed as "NYSEAMERICAN:LCTX".
Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is owned by 45.15% institutional shareholders and by 4.48% insiders. The rest is owned by the public.
Explore More Details on Lineage cell therapeutics, inc's “Ownership” Section
Lineage cell therapeutics, inc's key executive team includes the following managers:
Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is classified under the "Healthcare" sector and under the "Biotechnology" industry.
Currently the number of employees working for Lineage cell therapeutics, inc is 49.
Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is headquartered in CA, United States.
Lineage cell therapeutics, inc’s mailing address is 2173 Salk Avenue, Carlsbad, CA, United States, 92008.
The company’s phone number is 442 287 8990.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
